 Connection
Jeffrey Goldstein to Mixed Function Oxygenases
This is a "connection" page, showing publications Jeffrey Goldstein has written about Mixed Function Oxygenases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.108 |
|
|
|
-
Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001 Dec; 299(3):825-31.
Score: 0.203
-
Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther. 1999 Aug; 290(2):635-40.
Score: 0.173
-
Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, Goldstein JA. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther. 1998 Jan; 284(1):356-61.
Score: 0.155
-
Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997 Feb; 7(1):59-64.
Score: 0.146
-
Br?sen K, de Morais SM, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Pharmacogenetics. 1995 Oct; 5(5):312-7.
Score: 0.133
-
Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis. 2009 Jul-Aug; 43(1):119-28.
Score: 0.084
-
Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008 Feb; 83(2):312-21.
Score: 0.075
-
Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 1996 Oct; 24(10):1081-7.
Score: 0.036
-
Jurima-Romet M, Goldstein JA, LeBelle M, Aubin RA, Foster BC, Walop W, Rode A. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics. 1996 Aug; 6(4):329-39.
Score: 0.035
-
Edeki TI, Goldstein JA, de Morais SM, Hajiloo L, Butler M, Chapdelaine P, Wilkinson GR. Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans. Pharmacogenetics. 1996 Aug; 6(4):357-60.
Score: 0.035
-
de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther. 1995 Oct; 58(4):404-11.
Score: 0.033
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|